Akari Therapeutics Management
Management criteria checks 2/4
Akari Therapeutics' CEO is Rachelle Jacques, appointed in Mar 2022, has a tenure of 2.17 years. total yearly compensation is $1.56M, comprised of 39.5% salary and 60.5% bonuses, including company stock and options. directly owns 0.98% of the company’s shares, worth $114.06K. The average tenure of the management team and the board of directors is 1.7 years and 4.3 years respectively.
Key information
Rachelle Jacques
Chief executive officer
US$1.6m
Total compensation
CEO salary percentage | 39.5% |
CEO tenure | 2.2yrs |
CEO ownership | 1.0% |
Management average tenure | 1.7yrs |
Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Akari Therapeutics GAAP EPS of $0.00
Sep 27Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely?
Sep 20Akari Therapeutics announces positive results from pre-clinical studies of eye disease treatment
Jul 28Akari Therapeutics GAAP EPS of $0.00
Jul 20Patient completes course with Akari's stem cell transplant related complication treatment
Jul 07We're Keeping An Eye On Akari Therapeutics' (NASDAQ:AKTX) Cash Burn Rate
Dec 31Akari shares rise after FDA 'fast track' status for skin disease treatment nomacopan
Apr 28Akari Therapeutics reports FY results
Apr 21We Think Akari Therapeutics (NASDAQ:AKTX) Needs To Drive Business Growth Carefully
Mar 15Do Institutions Own Akari Therapeutics, Plc (NASDAQ:AKTX) Shares?
Jan 21Read This Before Selling Akari Therapeutics, Plc (NASDAQ:AKTX) Shares
Dec 17Akari Therapeutics updates trial progress; returns to profitability
Dec 11Akari Therapeutics' lead candidate shows encouraging preclinical action against inflammatory eye disease
Dec 03CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | US$2m | US$616k | -US$10m |
Sep 30 2023 | n/a | n/a | -US$10m |
Jun 30 2023 | n/a | n/a | -US$10m |
Mar 31 2023 | n/a | n/a | -US$14m |
Dec 31 2022 | US$4m | US$458k | -US$18m |
Compensation vs Market: Rachelle's total compensation ($USD1.56M) is above average for companies of similar size in the US market ($USD674.55K).
Compensation vs Earnings: Rachelle's compensation has been consistent with company performance over the past year.
CEO
Rachelle Jacques (52 yo)
2.2yrs
Tenure
US$1,560,141
Compensation
Ms. Rachelle Suzanne Jacques serves as President, CEO & Director at Akari Therapeutics, Plc since March 31, 2022. She serves as Non-Executive Director at uniQure N.V. since October 21, 2021. She serves as...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 2.2yrs | US$1.56m | 0.98% $ 114.1k | |
Interim Chief Financial Officer | less than a year | US$546.82k | no data | |
Chief Operating Officer | 1.8yrs | no data | no data | |
Chief Scientific Officer | no data | no data | no data | |
Executive VP & Chief Medical Officer | 1.5yrs | no data | no data |
1.7yrs
Average Tenure
54yo
Average Age
Experienced Management: AKTX's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 2.2yrs | US$1.56m | 0.98% $ 114.1k | |
Independent Director | 7.9yrs | US$77.12k | 0.13% $ 14.7k | |
Chairman | 8.7yrs | US$113.00k | 14.71% $ 1.7m | |
Independent Director | less than a year | US$35.18k | no data | |
Independent Director | less than a year | US$9.81k | 16.5% $ 1.9m | |
Independent Director | 6.3yrs | US$61.78k | 0.13% $ 14.7k |
4.3yrs
Average Tenure
63yo
Average Age
Experienced Board: AKTX's board of directors are considered experienced (4.3 years average tenure).